Major bleeding on an anticoagulant: what to do at once
- Haematological emergency
A patient on a blood thinner who bleeds into the head or loses a lot of blood can die within hours. Knowing the drug and its antidote saves the most time.
What it is
Major bleeding on an anticoagulant is bleeding that threatens life or a critical organ: inside the skull or spine, around the heart, into the airway, a muscle compartment or behind the abdomen, or bleeding that causes shock or needs transfusion. Management runs in parallel: resuscitate, stop the drug, find out which drug and when it was last taken, reverse it with the specific agent where one exists, and stop the bleeding at its source.
How to recognise it
- Major: haemodynamic instability, a critical site (brain, spine, pericardium, airway, eye, compartment, retroperitoneum) or a large fall in haemoglobin needing transfusion.
- Warfarin: intravenous vitamin K plus four-factor prothrombin complex concentrate; plasma only when concentrate is not available, since it is slower and needs a large volume.
- Dabigatran: idarucizumab; dialysis removes the drug if needed.
- Rivaroxaban, apixaban, edoxaban: andexanet alfa where available, otherwise prothrombin complex concentrate.
- Unfractionated heparin: protamine; low-molecular-weight heparin: protamine with partial effect; fondaparinux: no specific antidote.
- Head injury on an anticoagulant: low threshold for urgent CT, even with a normal examination.
What to do at once (and why)
- Airway, breathing, circulation; two large lines; send blood for group and crossmatch.
- Stop the anticoagulant and any antiplatelet drug.
- Identify the drug, the time of the last dose and the kidney function: they decide how much drug is left.
- Send count, PT/INR, aPTT, fibrinogen, creatinine and, where offered, a drug-specific level; do not wait for results to reverse in a critical bleed.
- Give the specific reversal agent for that drug at once in life-threatening or critical-site bleeding.
- Control the source: pressure, endoscopy, surgery or interventional radiology.
- Transfuse red cells as needed; give platelets, plasma or fibrinogen according to the tests.
- Plan restarting with the team once bleeding is controlled: the clot risk that justified the drug has not gone away.
Quick reversal guide
| Drug | Quick check | Specific reversal | Backup |
|---|---|---|---|
| Warfarin | INR | Vitamin K plus prothrombin complex concentrate | Plasma if concentrate is unavailable |
| Dabigatran | Thrombin time (normal = little drug) | Idarucizumab | Prothrombin complex concentrate, dialysis |
| Xa inhibitors | Calibrated anti-Xa; time since last dose | Andexanet alfa | Prothrombin complex concentrate |
| Unfractionated heparin | aPTT | Protamine | Time (short-acting) |
| Low-molecular-weight heparin | Anti-Xa | Protamine (partial) | Supportive care |
Costly mistakes
- Giving vitamin K alone for a major warfarin bleed: it takes hours to work; concentrate acts within minutes and vitamin K keeps the effect going.
- Giving concentrate without vitamin K: the INR climbs again once the concentrate wears off.
- Expecting plasma to reverse a DOAC: it adds volume but little effect against the drug.
- Reversing a high INR with concentrate in a patient who is not bleeding: holding warfarin, with or without oral vitamin K, is usually enough.
- Never restarting the anticoagulant out of fear: many patients have a higher risk of clots, stroke or death without it.
Tests and next step
- Repeat INR after concentrate and vitamin K to confirm reversal.
- Dabigatran: a normal thrombin time means little drug remains; kidney function predicts how fast the rest clears.
- Xa inhibitor: a calibrated anti-Xa level if available; otherwise use the last-dose time and kidney function.
- Watch for clots after reversal: concentrates and specific antidotes carry a thrombotic risk.
- Minor bleeding (nosebleed, bruising): local measures, check the INR or kidney function, and review the dose and other drugs; no reversal.
Common traps
- Waiting for clotting results before reversing in an intracranial bleed: reverse without waiting for them.
- Forgetting antiplatelet drugs and NSAIDs: ask about them, since they may be taken alongside the anticoagulant.
- Using tranexamic acid routinely in gastrointestinal bleeding: a large trial showed no benefit and more venous clots.
- Forgetting to ask when the last dose was taken: a DOAC taken many hours ago in a patient with good kidneys may already be mostly gone.
Test yourself
Think of the answer, then tap the question to see it.
Why is vitamin K given together with prothrombin complex concentrate when reversing warfarin in a major bleed?
Concentrate replaces the factors within minutes but wears off in hours; vitamin K lets the liver make its own factors, so the INR does not climb back.
A patient on dabigatran has a brain bleed. Which test shows whether drug is still present, and which agent reverses it?
The thrombin time (normal means little drug left); idarucizumab, an antibody fragment that binds dabigatran.
Why does kidney function matter so much in a patient bleeding on dabigatran?
Dabigatran is cleared mainly by the kidneys, so poor kidney function keeps it working longer; dialysis can remove it.
A patient on warfarin has an INR of 7 and no bleeding. Is prothrombin complex concentrate needed?
Usually not: hold warfarin, consider oral vitamin K and recheck the INR; concentrate is for serious bleeding or urgent surgery.
Elsewhere in DurgiPedia
- Bleeds on head CT: epidural, subdural, subarachnoid and intraparenchymal
- Upper and lower gastrointestinal bleeding
- Patients on anticoagulants: bleeding watch, monitoring tests, interactions and teaching
- Upper and lower GI bleeding: recognising it, monitoring, two lines and getting ready for endoscopy
- Hemorrhagic shock: compensation, vicious cycles and irreversibility
Connections
Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.
Sources: Perioperative Anticoagulation Management (StatPearls (NCBI Bookshelf), 2023); Interpretation of Blood Clotting Studies and Values (PT, PTT, aPTT, INR, Anti-Factor Xa, D-Dimer) (StatPearls (NCBI Bookshelf), 2025); Warfarin: MedlinePlus Drug Information (MedlinePlus, US National Library of Medicine, 2026); Dabigatran: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2025).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
